IMIrina I Marakhova

Irina I Marakhova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina I Marakhova has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CD25 expression on the surface of Jurkat cells

    by A. N. Shatrova, E. V. Mityushova, N. A. Aksenov, I. I. Marakhova

    Expression of the α-subunit of the interleukin-2 receptor (IL-2Rα) was assessed by quantifying CD25 upregulation in the Jurkat cell line (human acute T cell leukemia). It was found that phytohemagglut


    • 1 January 2013
      • Vol. 55  (5) , 300-6

    [The functional characteristics oF TRPV5 and TRPV6 channels in normal and transformed human blood lymphocytes].

    by V N Tomilin, I O Vasil'Eva, I I Marakhova, Iu A Neguliaev, C B Semenova

    Calcium signaling and Ca(2+)-conducting channels are involved in the development of immune response, cell proliferation, growth and differentiation of lymphocytes. In this paper the calcium channels TRPV5 and TRPV6 (transient receptor potential vanilloid channels) were studied in the plasma membrane of T cell line Jurkat and normal human blood lymphocytes. The channels were activated by removing Ca2+ and Mg2+ from surrounding solution, characterized by inward rectification, and were inactivated by the effective blocker of TRPV5 and TRPV6, ruthenium red. Channel activity was significantly higher in Jurkat cells, than in normal human lymphocytes. Quantitative PCR analysis revealed higher levels of mRNA genes encoding channels TRPV5 and TRPV6 in the proliferation cells compared with resting lymphocytes. In general these data showed that TRPV5/TRPV6 in human lymphocytes are functionally active, and their activity is associated with proliferative status of blood cells.


    • 1 January 2013
      • Vol. 55  (6) , 421-9

    [The STAT5 signaling in the expression of alpha-subunit of interleukin-2 receptor in human blood lymphocytes].

    by E V Mitiushova, A N Shatrova, V V Zenin, N D Aksenov, I I Marakhova

    The comparative study of the STAT3 and STAT5 activity (as assessed by tyrosine phosphorylation level) and the expression of a α-subunit of interleukin-2 receptor (as examined by cytophotometric evaluation of the number of CD25+ cells) during the phytohemagglutinin (PHA)-induced proliferation of human blood lymphocytes (HBL) have been made. It has been revealed that the level of STAT3 phosphorylation is high in both res ting and competent HBL and remains unchanged in the presence of PHA or interleukin-2 (IL-2). In contrast to STAT3, phosphorylation of STAT5 was not seen in both resting and competent HBL. We observed phosphorylation of STAT5 no earlier than 5 h after PHA stimulation and the maximum phosphorylation was detected following 24 h. Exogenous IL-2 induced high level of STAT5 phosphorylation in the competent HBL as early as at 30 min and this level of STAT5 phosphorylation kept in the next 24-48 h. The correlation between alterations in tyrosine phosphorylation level of STAT5 and the expression of CD25 has been established. WHI-P131, an inhibitor of JAK3 kinase, prevents STAT5 activation, cell surface expression of CD25 and lymphocyte proliferation. It has been concluded that JAK3/STAT5 signaling via IL-2 receptor is necessary to maintain the long-term expression of the high-affinity αβγ(c)-receptor of IL-2 and optimal proliferation of HBL.

    • 1 January 2011
      • Vol. 53  (8) , 645-51

    [The surface expression of CD25 at different stages of proliferative response in human lymphocytes. I. The role of JAK and Src tyrosine kinases as revealed by inhibitory analysis].

    by V V Zenin, N D Aksenov, A N Shatrova, E V Mitiushova, I I Marakhova

    The long-lasting expression of an alpha-subunit of interleukin-3 receptor (IL-2Ralpha) was found to accompany the PHA-induced proliferation of human blood lymphocytes (HBL), so that to the end of the second day of mitogenic stimulation only, the large blasts may express the high affinity alphabetagamma(c) receptor for IL-2. With the selective pharmacological drugs to JAK (WHI-P131) and Src (PP2) it is shown that the non-receptor tyrosine kinases are involved in the surface CD25 expression. It is revealed that the PP-2-inhibitable expression of CD25 is timely associated with the initial stage of T cell activation, whereas WHI-P131-inhibitable expression was present during the whole G0/G1/S transition. These data indicate that at the early, antigen-dependent stage the expression of IL-2Ralpha is induced via Src-dependent signaling pathway, and prolonged increase in IL-2Ralpha expression is regulated by IL-2/IL-2 receptor interaction via JAK-dependent signaling pathway.


    • 1 January 2011
      • Vol. 53  (8) , 652-8

    [The surface expression of CD25 at different stages of proliferative response in human lymphocytes. II. The role of interleukin-2].

    by A N Shatrova, V V Zenin, N D Aksenov, E V Mitiushova, I I Marakhova

    The expression of alpha-subunit of interleukin-2 receptor (IL-2Ralpha) was assessed by quantifying activation-induced upregulation of CD25 in human blood lymphocytes (HBL) stimulated by interleukin-2 (IL-2). It was established that exogenous IL-2 induced no surface expression of CD25 neither proliferation at 48 h of IL-2 action. In component HBL, pretreated by sub-mitogenic doses of phytohemagglutinin (PHA), 5-15 % of cell population was revealed to represent the CD2t+ cells, and in the competent cells only, exogenous IL-2 induced the surface expression of CD25 as well as the growth and the proliferative response, which was comparable with those to mitogenic doses of PHA. The JAK3 inhibitor WHI-P131 eliminated IL-2-dependent CD25 expression without influencing the CD25 expression in competent cells. Unlike, PP2 was found to inhibit the IL-2-dependent CD25 expression in a lesser extent than WHI-P131, however this drug was effectively inhibited CD25 expression in PHA-pretreated, competent HBL. These data suggest that Src-dependent signaling participate in the early IL-2Ralpha expression that precedes the IL-2-dependent cell cycle progression of activated HBL. It is concluded that in normal T cells, the IL-2Ralpha expression in firstly induced by antigen (mitogen) and thereafter it is held IL-2 through JAK-dependent signaling pathway.


  • Long-term regulation of Na,K-ATPase pump during T-cell proliferation

    by Inna Karitskaya, Nikolay Aksenov, Irina Vassilieva, Valerii Zenin, Irina Marakhova

    The aim of the study was to elucidate the mechanism responsible for the proliferation-related regulation of Na,K-ATPase pump. Our data demonstrate that in mitogen-stimulated human blood lymphocytes, enhanced ouabain-sensitive Rb(K) fluxes in the middle/late stage of G0/G1/S transit are associated with the increased number of Na,K-ATPase pumps expressed at the cell surface (as determined by the [3H]ouabain binding). Analysis of total RNA (reverse transcription-polymerase chain reaction) and protein (Western blotting) showed a threefold increase in the level of Na,K-ATPase α1-subunit and β1-subunit mRNAs and significant increase in the Na,K-ATPase α1-subunit protein during the first day of mitogen-induced proliferation. The elevated K transport as well as the increased expression of Na,K-ATPase is closely associated with the IL-2-dependent stage of T-cell response. The pharmacological inhibition of IL-2-induced MEK/ERK or JAK/STAT cascades suppressed the IL-2-induced proliferation and reduced the functional and protein expressions of Na,K-ATPase. It is concluded that during the lymphocyte transition from resting stage to proliferation, (1) long-term activation of Na,K-ATPase pump is due to the enhanced expression of Na,K-ATPase protein and mRNA, and (2) the cytokine signaling via the IL-2 receptor is necessary for the cell cycle-associated upregulation of Na,K-ATPase.


  • STAT5 in regulation of chronic leukemia K562 cell proliferation: Inhibitory effect of WHI-P131

    by E. V. Mityushova, N. D. Aksenov, I. I. Marakhova

    In this study, we examined the role of JAK/STAT signaling in the regulation of chronic leukemia K562 cell proliferation. STAT3 and STAT5 tyrosine phosphorylation was used as a marker of the activation status of STAT proteins. We demonstrated that, in growing cultures of K562 cells, both STAT3 and STAT5 are constitutively activated. To determine the significance of STAT activity in maintaining the high level of K562 proliferation, we tested two JAK inhibitors, AG-490 (JAK2 and JAK3 inhibitor) and WHI-P131 (a new specific JAK3 inhibitor). We showed that, during the prolonged cultivation (48 h) of K562 cells with AG-490 or WHI-P131, the cells remained viable. It was found that treatment with WHI-P131 (30–100 μM) decreased tyrosine phosphorylation of STAT5 and did not affect the high level of STAT3 phosphorylation. In proliferating K562 cells, AG-490 (25–50 μM) did not influence on STAT3 and STAT5 phosphorylation. The flow cytometry analysis revealed a dose-dependent decrease in G1 and S phases and an increase in G2/M phases in WHI-P131-treated K562 cells and no changes in cell cycle structure in AG-490-treated cultures. Thus, our findings indicate the preferential role of STAT5 (not constitutively active STAT3) in the proliferation of leukemia K562 cells and demonstrate the specificity of WHI-P131 inhibitory effect; unlike other JAK drugs that stimulate apoptosis and decrease proliferation, WHI-P131 prevents K562 cells growth by arresting in G2/M phases of the cell cycle.


    • 1 January 2010
      • Vol. 52  (2) , 184-90

    [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131].

    by E V Mitiushova, N D Aksenov, I I Marakhova

    In this study, we examined the possible role of JAK/STAT signaling pathway in regulation of proliferation of chronic leukemia cells K562. The thyrosine phosphorylation of STAT3 and STAT5 was used as a marker of an activation status of STAT proteins. We demonstrate that in growing culture of K562 both STAT3 and STAT5 are constitutively activated. To determine the significance of STATs activity in maintaining the high level of K562 proliferation we tested two JAK inhibitors: AG-490 (JAK2 and JAK3 inhibitor) and WHI-P131 (a new specific JAK3 inhibitor). We showed that in long-tern cultures (48 h) of K562 cells with AG-490 or WHI-P132 the cells remain viable. It was found that treatment with WHI-P131 (30-100 microM) decreased the thyrosine phosphorylation of STAT5 being without effect on the high level of STAT3 phosphorylation. In proliferating K562 cells, AG-490 (25-50 microM) did not influence STAT3 and STAT5 phosphorylation. The flow cytometry analysis revealed a dose-dependent decrease in G1 and S phases and an increase in G2/M phases in WHI-P131-treated K562 cell cultures and no changes in cell cycle structure in AG-490-treated cells. Thus, our findings indicate a preferential role for STAT5 (not constitutively active STAT3) in proliferation of leukemia to other JAK drugs which stimulate apoptosis and decrease proliferation, WHI-P131 prevents K562 cells growth by arresting in G2/M phases of cell cycle.


  • Time-dependent expression of CD25 in phytohemagglutinin- or interleukin-2-stimulated human peripheral blood lymphocytes

    by V. V. Zenin, N. D. Aksenov, A. N. Shatrova, I. I. Marakhova

    The dynamics of the expression of the high-affinity receptor for interleukin-2 (IL-2 receptor) evaluated by the method of flow cytofluorimetry based on changes in the number of cells that express the CD25 marker (CD25+) was studied in human peripheral blood lymphocytes stimulated by various mitogens. It has been shown that, in the resting lymphocyte culture, both phytohemagglutinin (PHA, 10 μg/ml) and 12,13-phorbol dibutyrate (PDBu, 10−8 M) with ionomycin (IM, 5 × 10−7 M) induce a long-lasting increase (for 48 h) in the number of CD25+ cells. Interleukin-2 (IL-2) has only been found to be capable of inducing time-dependent CD25 expression in competent (not resting) lymphocytes pretreated with submitogenic doses of PHA (1 μg/ml). A comparison of the dynamics of the number of CD25+ cells and blast transformation has shown that CD25 markers are revealed as early as on small stimulated lymphocytes, while, at the late activation stages, which correspond to the stage of cell growth and transition to DNA synthesis, the overwhelming majority of blasts are CD25+ cells with high-affinity α -receptors for IL-2. The obtained data allow one to suggest that the expression of an α -subunit of IL-2 receptor takes place at the IL-2-dependent stage of T lymphocyte proliferation and may be directly induced by IL-2 via IL-2 receptor.

    • 1 January 2009
      • Vol. 51  (6) , 506-10

    [The expression of CD25 in phytohemagglutinin- or interleukin-2-stimulated human peripheral blood lymphocytes].

    by V V Zenin, N D Aksenov, A N Shatrova, I I Marakhova

    The timely expression of a high affinity receptor for interleukin-2 (IL-2R) in human peripheral blood lymphocytes stimulated by various mitogens was examined by cytophotometric evaluation of the number of CD25 bearing cells (CD25+). In resting lymphocyte culture both phytohemagglutinin (PHA, 10 (microg/ml) and 12,13-phorbol dibutirate (PDBu, 10-8 M) and ionomycin (IM, 5 x 10(-7) M) induce the long-lasting increase (during 48 h) in the number of CD25+ cells. Only in competent (not in resting) lymphocytes, pretreated by submitogenic doses of PHA (1 microg/ml), interleukin-2 (IL-2) is capable to induce the time-dependent CD25 expression. When comparing the time course of CD25+ expression and the blasttransformation it was found that the CD25 markers were revealed on small stimulated lymphocytes and all the large blasts were the CD+ cells with high-affinity alphabetagamma(c) receptor for IL-2. In conclusion, the expression of alpha-subunit of IL-2R takes place during the IL-2-dependent stage of T cell proliferation and may be directly induced by IL-2 via IL-2R.